Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Systemic failings in information sharing across Jersey's healthcare system led to "neglectful" and "distressing" delays to ...

The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...

According to a spokesperson for Neal Dunn the FAIC Act aims to guarantee that Medicare cancer patients have access to the ...

Physical and psychological recovery and beyond ...

SNV4818 is an oral treatment currently being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors.

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to bolster its oncology pipeline.